Ultragenyx anticipates 2 gene therapy PDUFAs in August/September 2026 while targeting profitability in 2027 (NASDAQ:RARE)
· seekingalpha.com
Ultragenyx (RARE) Q2 2026 earnings call: record revenue, reaffirmed guidance, key PDUFA dates for DTX401/UX111 and GTX-102 data—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...